1. Home
  2. OBIO vs OPP Comparison

OBIO vs OPP Comparison

Compare OBIO & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

HOLD

Current Price

$4.21

Market Cap

237.2M

Sector

Health Care

ML Signal

HOLD

Logo RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

OPP

RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

HOLD

Current Price

$7.86

Market Cap

198.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBIO
OPP
Founded
2017
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
237.2M
198.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OBIO
OPP
Price
$4.21
$7.86
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$14.25
N/A
AVG Volume (30 Days)
217.8K
108.0K
Earning Date
11-10-2025
01-01-0001
Dividend Yield
N/A
14.41%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,818,000.00
N/A
Revenue This Year
$35.75
N/A
Revenue Next Year
$3.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.46
N/A
52 Week Low
$2.20
$7.26
52 Week High
$6.16
$8.83

Technical Indicators

Market Signals
Indicator
OBIO
OPP
Relative Strength Index (RSI) 45.38 41.34
Support Level $4.06 $7.88
Resistance Level $4.53 $8.01
Average True Range (ATR) 0.30 0.08
MACD -0.03 0.00
Stochastic Oscillator 24.88 11.11

Price Performance

Historical Comparison
OBIO
OPP

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.

Share on Social Networks: